What Researchers Did
Researchers reviewed current evidence on the mechanisms and therapeutic potential of hyperbaric oxygen therapy (HBO) in modulating autophagy in cerebral ischemia-reperfusion injury (CIRI).
What They Found
They found that hyperbaric oxygen therapy (HBO) modulates autophagy through AMPK-mTOR, HIF-1α-mTOR, and PI3K-AKT pathways, playing a dual role in cell survival or injury. Preclinical studies demonstrate HBO upregulates LC3-II and Beclin-1 while downregulating p62, indicating enhanced autophagy, and clinical trials like OPENS-2 suggest synergistic effects with endovascular therapy.
What This Means for Canadian Patients
Hyperbaric oxygen therapy (HBO) shows promise as a potential treatment to mitigate neuronal injury in Canadian patients experiencing cerebral ischemia-reperfusion injury. If validated, HBO could offer a new therapeutic option, possibly in combination with existing treatments like endovascular therapy, to improve patient recovery.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
Limitations include the lack of standardized biomarkers and optimal treatment parameters for hyperbaric oxygen therapy, necessitating future large-scale randomized controlled trials.